Table 3 Inhibition of EV-A71 viral infectivity by silymarin and baicalein from virucidal, cell protection and comprehensive assays
From: Antiviral activity of silymarin in comparison with baicalein against EV-A71
Compound (Concentration) | Quantification | Virucidal assay | Cell protection assay | Comprehensive assay |
|---|---|---|---|---|
Silymarin (100 μg/mL) | Plaque assay | 94.0% | 16.6% | 100.0% |
qRT-PCR | 84.3% | 19.9% | 97.0% | |
Baicalein (54 μg/mL) | Plaque assay | 65.0% | 2.2% | 89.4% |
qRT-PCR | 78.8% | 0.0% | 83.0% |